Black populations suffered 1.6 million excess deaths in the past 20 years, new studies find; the Federal Trade Commission (FTC) sues to block Amgen from acquiring Horizon Therapeutics, citing 2 drugs that have no competition; cancer drug shortages are approaching an all-time high.
Black Communities Experienced Excess Deaths in Past 20 Years, Say Studies
America’s Black communities endured an excess 1.6 million deaths compared with the White population during the past 20 years, costing hundreds of billions of dollars, according to 2 new studies that expand on what is known about health disparities and inequity, reported The Washington Post. According to the reports published Tuesday in JAMA, the unequal nature of American society affecting social determinants of health—good schools, safe housing, employment with a living wage, health care, and more—is to blame.
FTC Sues to Prevent Monopolizing Acquisition
The Federal Trade Commission (FTC) is looking to stop Amgen Inc. from acquiring Horizon Therapeutics plc, saying the deal would allow Amgen to leverage its drug portfolio to bolster the monopoly positions of Horizon medications teprotumumab and pegloticase, used to treat thyroid eye disease and chronic refractory gout, respectively. The FTC's lawsuit said the deal would allow Amgen to use rebates to pressure insurance companies and pharmacy benefit managers into favoring the 2 treatments, which have no competition.
Drug Shortages Approaching All-Time High
Thousands of patients are encountering delays in getting treatments for cancer and other deadly diseases, with drug shortages in the United States nearing record levels, according to The New York Times. The shortages are getting the attention of the White House and Congress, which are studying the underlying causes of the wavering generic drug market, which accounts for about 90% of US prescriptions.
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More